Sponsors



Main

September 20, 2007

Vivisection at Berkeley: Protest all life sciences!

Recently, a group of student-organized protesters picketed on-campus and outside the Helen Wills 10th anniversary symposium. The Helen Wills Institute is a neuroscience institute with affiliated labs on the Berkeley campus. Most of the animal protesters wore bandanas over their faces and carried signs like "vivisection kills" and wrote on the sidewalks phrases like "animals die while demons rejoice." I have come to the conclusion that protesting like this is an unhelpful contribution to on-campus activism as well as a distraction from a fruitful animal-research debate.

Continue reading "Vivisection at Berkeley: Protest all life sciences!" »

February 28, 2006

Today's seminar: Irving Weissman on stem cells

Today, Irving Weissman gave the Marian Koshland seminar here at Berkeley. Weissman is the Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford. He was also recently featured in The New York Times (see also here). The title of his talk was "Stem cells: Units of regeneration, units in cancer and units of natural selection." He's a pioneer in the science of stem cells (having isolated and characterized the differentiation of the blood-forming cells); he also gives an awesome talk.

He started with an introduction to stem cells, then discussed how stem cells have been implicated in acute myeloid leukemias. His aim is to understand why 2-3% of tumor cells have properties similar to self-regenerating stem cells, and from all appearances, he is making progress. By regulating the expression profiles of hematopoeitic stem- and progenitor-cells, his lab is able to precisely control and induce cancers in a controlled way, including regulating the proliferation of monocytes from chronic myelomonocytic leukemia to acute myeloid leukemia (I hope I got that right!). This is a nice system because they can change exactly which expression program the cell is running at any given time, and observe the results in mice. It might not lead to immediate cures for cancer, but it will certainly help pinpoint how cells become neoplastic (cancerous), step-by-step. This could eventually lead to prophylactic treatments to destroy cells that are pre-cancerous.

But the highlight of his talk was his work on human neural stem cells. He injected human neural stem cells into mice, and they began to behave in certain ways just like mouse brain cells. They responded "correctly" to their microenvironment, differentiating into the proper cell forms and moving about in the mouse brain just as the mouse cells would have. These stem cells displayed plasticity and could repair spinal cord injuries. This is huge. It's easy to see that with some work, obtaining and culturing human neural stem cells could yield fantastic advances for victims of spinal cord injuries(†).

Lastly, Weissman discussed a new model species—the protochordate Botryllus schlosseri—in which the somatic stem cells were under natural selection separately from the germline. He found a receptor in this species that may turn out to be an analog to a natural receptor for NK cells in vertebrates; he speculated that this putative NK receptor could help explain why transplant rejection occurs in some patients despite apparently good matches for the traditional cell surface antigens.

Stay tuned, there is still so much to be learned about human physiology at the cell level. We are just at the very beginning.

(†) Weissman repeatedly noted that President Bush would call these experiments "abominations" because he is creating, after all, "human-animal hybrids." He was quick to point out that an individual's personal ethics could not possibly justify preventing research into life-saving treatments for others.

February 21, 2006

Stem cells and cancer: HodgesLab bests NYT

You heard it here first, readers.

The New York Times is running an article today entitled "Stem Cells May Be Key to Cancer." Go read it; it's definitely worth a couple minutes' time.

Nineteen days ago, I posted this report to HodgesLab called "Are cancers broken stem cells?"

Times 0, HodgesLab 1.

Why basic research is clinically relevant

Many scientists I know have trouble explaining to laypeople why basic research is important. The fact of the matter is that not everybody in biology is working to cure a disease, not everyone in chemistry is making pharmaceuticals, and physicists aren't all working on quantum computing. It's difficult to respond positively to these assumptions, in part because most scientists do feel like they're making a contribution — but to explain that contribution means teaching a mini-review course in some area of science that has its own unique jargon.

So it's nice to have freebie examples of why basic research is so necessary. Typically, I think of quantum mechanics and how it seemed so exotic and far-removed from everyday life back in the 1910's and 20's. Now, however, we couldn't go a day without quantum mechanics: what with computers, LEDs, lasers, etc.

But for a biologist it can be even more challenging ("why study so-and-so if you could be curing a disease?"). I recently found one example of work in basic cell biology that has immediate contribution to cancer biology: Medical News Today reviews an article by researchers at HHMI/UPenn that study the cellular response to hypoxia (lack of oxygen). Their findings have implications for treatment of solid tumors (i.e. cancers that are not lymphomas, leukemias, or other cancers of the blood), where the tumor cells grow in hypoxic environments:

In addition to hypoxia, solid cancer tumors are comprised of abnormal cells and convoluted blood vessels, which allow the tumors to resist chemotherapy and radiation treatments. New treatments for cancer are now aiming to turn off [hypoxic response] activity, halting the ability of the cell to signal its low-oxygen alert system and undergo protein synthesis

So in doing basic cellular biology research, they realize that their findings might be used in the treatment of cancer. Results like these are strong arguments for why NIH and NSF should stay well funded — no corporation would have the R&D funding to support research like this, because the results aren't immediately profitable. However, work like this leads to treatments for cancer...

[PubMed link to research article here]

February 20, 2006

The virus is a complex nanomachine

Consider this question: if you wanted to build a virus de novo, what would be first on your parts-list? I don't mean this to sound like a bio-defense fellowship application, but instead I mean to ask, how much do we know, mechanically, about common viruses?

I'll start with what I think is the most important piece: a DNA (or RNA) packaging motor. The reason I think this is so critical is because the virus, at its simplest, is a structurally sound and chemically stable genome. Somehow after replication a virus must package into its daughter an entire copy of its genome. So how does the nucleic acid get in there?


Image courtesy Nature, Jiang Lab

If we wanted to build a virus, we obviously would need some sort of biological motor. One that can latch on somewhere, recognize viral (and not cellular!) DNA, then shove it into the empty viral shell. What specifications should we consider for this motor? Since this packaging motor needs some sort of energy input, I think it would be wise to use the host cell's ATP store. After all, it's just sitting around, right? What about once this virus particle find the next target cell; it will want to inject its DNA into that cell. Unfortunately for us, there isn't going to be much ATP lying around outside cells (not even in blood).

Luckily, nature has already solved this dilemma, and we can find out how if we ask the right questions. It turns out that you can monitor actual viral DNA packaging motors using optical tweezers, and gain some insights about how the virus operates. And this is something that the Bustamante lab here at Berkeley does very well. We've managed to measure the forces exerted by a single packaging motor of phi29, a bacteriophage (read "virus for bacteria").

The authors of this paper found that even a single motor can generate enormous forces when packaging DNA (well, enormous by biological standards). Using ATP alone, it can exert forces up to 50 pN (that's 50×10-12 Newtons), which is astonishing for its size. By comparison, each molecule of myosin, the force-generating protein in your muscles, can generate a force of only 5 pN. Which means that the packaging motors in the bacteriophage are about 10 times stronger than an equivalent number of your myosin motors.

The authors did a quick back-of-the-envelope calculation that suggested the DNA inside the virus must be at a pressure equivalent to 60 atmospheres. The raison d'etre of the motor became clear—when the new virus finds a host cell, it must pop open like a champagne bottle and allow its DNA to shoot into the new target cell. The virus relies on this mechanism to infect a new cell precisely because there is no ATP (and therefore no energy source) available outside the target cell. Ingenious!

It turns out this calculation provided a prediction that was testable. It suggested that DNA inside virii should be so dense that it ought to have almost crystalline order, something DNA normally resists very much. And a recent paper from Nature provides confirmation of this prediction through cyro-electron microscopy. It appears that the DNA is so well ordered that electron microscopy imaging can make out the pattern inside the virus. Seed Magazine has a fascinating, and less technical, breakdown of this work on their site.

There is much insight to be gained by considering biological objects as mechanical devices. In my opinion, cell biology and biophysics is diverging into two complementary paths: (1) understanding the physical basis of biological activity, and (2) understanding how redudant, overlapping signalling pathways give rise to robust decision-making networks. Of course synthetic biology sometimes attempts to bridge this gap, by creating biology that performs some novel task.

Comments are open. Your thoughts?

Poor, heal thyself

Nick Anthis (the Texas A&M biochem grad who broke the George Deutsch graduation story) and Jim Hu comment on the recent NYT article about the price Genentech charges for Avastin. Nick claims this is an example of drug companies sticking it to the poor, while Jim follows up with a reminder of how long Avastin has been in development.

Avastin is a monoclonal antibody (mAb) treatment (something I've written about before). These mAb's are now usually produced in cell culture by hybridomas with humanized mouse B lymphocytes. So we are talking about a drug that will be more complex, more delicate and therefore more costly to produce than traditional organic syntheses. It's also worth noting that Avastin is not a miracle drug for colon cancer, but it does increase survival.

In all, I'm inclined to side with Jim on this. I think the whole debate about drug costs comes down to how much an individual trusts market forces. And while it's a bit touchy to apply this line of thinking to cases of life-or-death, there still are some fundamental economic reasons for letting the market decide the costs of goods.

For example, if Genentech makes a "killing" by selling Avastin, then Genentech makes a large profit. The shareholders of Genentech are intelligent people, and they know that it would be smart to parlay that profit into other drugs that also make profits, rather than to take the money and run. Those not afraid of capitalism know that the one virtue of free markets is that they keep people working on profitable ventures. In the case of drug companies, this means that healthy profits lead to more drugs, and also more competitors making other drugs. Unless the company is poorly managed, I can't justify how this is bad.

To make pharmaceuticals unprofitable would be a solution that's worse than the problem. But, as Jim says, "No one complains about the cost of things that don't exist."

February 2, 2006

Are cancers broken stem cells?

Are cancers broken stem cells? I've been on a tear with cancer, I know, but I had to share a recent article. In last month's Journal of Investigative Dermatology, researchers at Duke University Medical Center published a paper in which they proposed that melanoma cancers may just be stem cells "stuck" in the wrong mode. Pretty interesting idea, as it ties a lot of loose ends that have been floating around in therapeutic biology.

Of course the big difference between plain ol' somatic cells and stem cells is that most somatic cells are in stationary mode. That means that, unlike stem cells, most of your body's cells are just sitting there, operating just above equilibrium but most importantly, not dividing (†). Stem cells possess the ability to continually divide as well as commit their daughter cells into particular "modes." Because they are constantly dividing, it's not too far of a stretch to imagine that the cells in a tumor (which are also continually dividing) may be running a "corrupted program" of what stem cells normally run.

If true, this would argue that molecular/developmental biology approaches might be better suited to pinpoint the errant cell processes. We know cells run complicated metabolic/gene expression programs, and we've had some successes in differentiating and even de-differentiating stem cells. So if we were to approach cancer like we do with the development and differentiation of stem cells—a field in which we've made some progress—then maybe we could get a better handle on cancer. Maybe even program tumors to stop proliferating by exposing them to the right cocktail of proteins or small-molecule drugs.

With science, the correct model is everything. When we get it, all the previous work starts to make sense and things just work. Is the model of cancer as a miswired stem cell the right model? There are some morphological similarities and functional similarities. We'll have to wait and see...

(†) This distinction is critical and is why chemotherapy works. Since chemo attacks dividing cells, it preferentially affects the tumor. It's also why chemo sucks: you're weak, your immune system sucks and your hair falls out... unlike most somatic cells, hematopoietic (blood-generating) and hair-follicle progenitor cells constantly divide and are also affected by the chemotherapy.

January 28, 2006

Cancer+Immunology.

Cancer+Immunology. This spring I'm taking a seminar called Cancer and Immunology. In the seminar, we discuss recent advances in immunity-based treatments for cancer.

I—being the odd guy out who has never formally taken an immunology course—naturally got tapped to be the second speaker. But, but, my sweet Lord, this is an exciting field. I had no idea where the field was at until reading these papers...

BERH-2-B is the experimental group, BERH-2 is the control groupOne of the papers was written as long ago as 1994. The researchers knew at the time that certain tumor cells are detected and automatically destroyed by the immune system, while others evade immune surveillance. Of course, those aberrant cells that evade the immune system can continue unchecked growth, which nobody wants. The researchers hypothesized that if they cultured tumor cells ex vivo and fused them with a particular type of white blood cell, that this fused hybrid cell might jumpstart the immune system and serve as an effective vaccine against the cancer.

They do exactly this in lab rats, using a chemically induced liver cancer cell line. The long and short of it is that their procedure resulted in 75% survival rate for immunized rats, compared to a 0% survival rate for the control group. The "vaccine" even worked if it was given after implantation of the tumor.

This would have incredible consequences if it ever worked in human patients. If you developed certain types of cancer, imagine that you could go to a lab and have two biopsies done. Two weeks later, you drive to your oncologist for a subcutaneous injection of some of these cells back under your skin. Within days, your own immune system suddenly begins to attack your tumor, and you may go into remission possibly without ever undergoing chemotherapy.

It may be a long, long way off, but these types of treatments are certainly in the pipeline... exciting times!